[weglot_switcher]
Access tomorrow’s cancer treatments today — safely guided by our oncology specialists.
Clinical trials test new cancer treatments for safety and effectiveness.
OncoCare Malaysia conducts Phase 2 and Phase 3 trials for advanced cancer therapies.
All studies are approved and monitored by Ethics Committees and relevant Malaysian health authorities.
Eligible patients may access new treatments not yet commercially available.
Clinical trials are carefully regulated studies that help doctors evaluate and improve cancer treatments. They follow international Good Clinical Practice (GCP) guidelines and provide patients with safe access to new investigational therapies. By participating, patients may receive treatments that are not yet widely available while contributing to future advances in oncology.
Tests a new drug or treatment in a small group of participants to determine its safety, dosage range, and potential side effects.
Typically conducted in specialised research centres before wider patient studies
Evaluates how well the new treatment works for specific cancers. Patients are closely monitored for treatment response and side effects.
Compares the new treatment with standard therapy to confirm effectiveness, monitor side effects, and collect data across larger patient groups.
All clinical trials at OncoCare Malaysia are approved by ethics committees and monitored by health authorities, including the Ministry of Health Malaysia, in accordance with international Good Clinical Practice (GCP) standards. Each study follows strict research protocols to protect patient safety, ensure scientific integrity, and maintain transparency throughout the trial process.
Your safety is our priority. Every trial is:
Study Title | Principal Investigator | Study Status | Clinicaltrials.gov |
|---|---|---|---|
A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN). |
Dr John Low Seng Hooi |
Recruitment start Q3 2025 | |
Protocol ArriVentBiopharma-0H24GE: A Global, Phase 3, Randomized, Multicenter, Open Label Study To Evaluate The Efficacy And Safety Of Firmonertinib Compared With Osimertinib As Firstline Treatment In Participants Who Have Locally Advanced Or Metastatic Non-small-cell Lung Cancer With Epidermal Growth Factor Receptor P-loop And Alpha C-helix Compressing (PACC) Mutations. |
Dr John Low Seng Hooi |
Recruitment start Q3 2025 |
Yet to have information |
